Zentalis is a clinical-stage biopharmaceutical company developing small molecule therapeutics that target key biological pathways in cancer, specifically utilizing WEE1 inhibition to treat various malignancies. Their therapies aim to improve outcomes for patients with platinum-resistant ovarian cancer and other solid tumors, addressing the need for effective treatment options in challenging cancer types.
Funding
$235.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many cancers lack effective treatment options, particularly platinum-resistant ovarian cancer and other solid tumors with Cyclin E1 overexpression. Current therapies often fail to adequately target key biological pathways driving cancer progression, leading to poor patient outcomes.
Solution
Zentalis Pharmaceuticals is developing small molecule therapeutics, including azenosertib (ZN-c3), a WEE1 inhibitor, designed to target fundamental biological pathways in cancer cells. Azenosertib is being evaluated as a monotherapy and in combination with other agents across multiple tumor types, with a focus on Cyclin E1+ platinum-resistant ovarian cancer (PROC). Clinical trials have demonstrated promising anti-tumor activity and a manageable safety profile for azenosertib as a single agent. The company is also exploring the potential of azenosertib in combination with microtubule inhibitor-based antibody-drug conjugates (ADCs) and other chemo backbones. By selectively inhibiting WEE1, Zentalis aims to disrupt the DNA damage response and induce cancer cell death, offering a novel approach to improve outcomes for patients with difficult-to-treat malignancies.
Target Audience
The primary target audience includes patients with Cyclin E1+ platinum-resistant ovarian cancer (PROC), other solid tumors, and the physicians who treat them, particularly gynecologic oncologists.
Features
- Azenosertib (ZN-c3): A selective WEE1 inhibitor with potential as a first-in-class therapy
- Targets Cyclin E1+ platinum-resistant ovarian cancer (PROC) and other solid tumors
- Evaluated as monotherapy and in combination with other anti-cancer agents
- Clinical trials demonstrate objective response rates (ORR) of >30% in Cyclin E1+ PROC
- FDA Fast Track Designation for azenosertib in Cyclin E1+ PROC patients
- DENALI study: A registration-intent trial evaluating azenosertib in PROC
- Synergistic antitumor effects in combination with topoisomerase 1 inhibitor-based antibody-drug conjugates (ADCs)
- Biomarker-driven clinical strategy focusing on Cyclin E1/CDK2 activation as a predictor of sensitivity to azenosertib